The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.

Domenica Lorusso, MD, PhD, discusses the rationale behind the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Domenica Lorusso ...

A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina Gasparetto, MD, ...

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...

STC-15, an investigational RNA methyltransferase inhibitor, has shown promising clinical activity and an encouraging safety ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study ...